Business Context and Reporting Period
Envoy Medical, Inc. (Nasdaq: COCH) filed a Form 8-K on November 26, 2025, reporting the results of a Special Meeting of Stockholders held on that date. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The primary material event reported is the successful shareholder approval of an "Issuance Proposal" required to comply with Nasdaq Listing Rule 5635(d). This approval authorizes the issuance of warrants to purchase Class A Common Stock and the underlying shares pursuant to a securities purchase agreement dated September 22, 2025, and an engagement letter with H.C. Wainwright & Co., LLC dated September 17, 2025.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies were disclosed beyond the standard regulatory context of the stockholder vote. The authority to adjourn the meeting to gather votes was approved but not utilized.
Investor Verification Checklist
- Voting Results: Verify the final tally for the Issuance Proposal (13,599,174 For vs. 243,009 Withheld) and the Adjournment Proposal (13,345,775 For vs. 247,335 Withheld).
- Transaction Details: Review the specific terms of the securities purchase agreement dated September 22, 2025, to understand the dilution impact of the approved warrants.
- Compliance Status: Confirm that the issuance of warrants and underlying shares proceeds in accordance with the approved Nasdaq Listing Rule 5635(d) exemption.
- Broker Non-Votes: Note the presence of broker non-votes (5,700 for the Issuance Proposal; 6,064 for the Adjournment Proposal) which did not affect the outcome.